337 related articles for article (PubMed ID: 30557916)
1. Efficacy of novel β
Yoshida M; Takeda M; Gotoh M; Yokoyama O; Kakizaki H; Takahashi S; Masumori N; Nagai S; Hashimoto K; Minemura K
Int J Urol; 2019 Mar; 26(3):369-375. PubMed ID: 30557916
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety and efficacy of the novel β
Yoshida M; Kakizaki H; Takahashi S; Nagai S; Kurose T
Int J Urol; 2018 Jul; 25(7):668-675. PubMed ID: 29752752
[TBL] [Abstract][Full Text] [Related]
3. Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial.
Mitcheson HD; Samanta S; Muldowney K; Pinto CA; Rocha BA; Green S; Bennett N; Mudd PN; Frenkl TL
Eur Urol; 2019 Feb; 75(2):274-282. PubMed ID: 30661513
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of vibegron, a novel β3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study.
Yoshida M; Takeda M; Gotoh M; Yokoyama O; Kakizaki H; Takahashi S; Masumori N; Nagai S; Minemura K
BJU Int; 2020 May; 125(5):709-717. PubMed ID: 31991511
[TBL] [Abstract][Full Text] [Related]
5. Vibegron, a Novel Potent and Selective β
Yoshida M; Takeda M; Gotoh M; Nagai S; Kurose T
Eur Urol; 2018 May; 73(5):783-790. PubMed ID: 29366513
[TBL] [Abstract][Full Text] [Related]
6. Editorial Comment to Efficacy of novel β
Kitta T
Int J Urol; 2019 Mar; 26(3):375-376. PubMed ID: 30557905
[No Abstract] [Full Text] [Related]
7. International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR.
Staskin D; Frankel J; Varano S; Shortino D; Jankowich R; Mudd PN
J Urol; 2020 Aug; 204(2):316-324. PubMed ID: 32068484
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of Vibegron in treating overactive bladder: A systematic review and pooled analysis of randomized controlled trials.
Shi H; Chen H; Zhang Y; Cui Y
Neurourol Urodyn; 2020 Jun; 39(5):1255-1263. PubMed ID: 32421908
[TBL] [Abstract][Full Text] [Related]
9. Once-Daily Vibegron 75 mg for Overactive Bladder: Long-Term Safety and Efficacy from a Double-Blind Extension Study of the International Phase 3 Trial (EMPOWUR).
Staskin D; Frankel J; Varano S; Shortino D; Jankowich R; Mudd PN
J Urol; 2021 May; 205(5):1421-1429. PubMed ID: 33356445
[TBL] [Abstract][Full Text] [Related]
10. Once-daily oxybutynin patch improves nocturia and sleep quality in Japanese patients with overactive bladder: Post-hoc analysis of a phase III randomized clinical trial.
Yokoyama O; Yamaguchi A; Yoshida M; Yamanishi T; Ishizuka O; Seki N; Takahashi S; Yamaguchi O; Higo N; Minami H; Masegi Y
Int J Urol; 2015 Jul; 22(7):684-8. PubMed ID: 25782032
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular safety of vibegron, a new β3-adrenoceptor agonist, in older patients with overactive bladder: Post-hoc analysis of a randomized, placebo-controlled, double-blind comparative phase 3 study.
Yoshida M; Takeda M; Gotoh M; Yokoyama O; Kakizaki H; Takahashi S; Masumori N; Nagai S; Minemura K
Neurourol Urodyn; 2021 Aug; 40(6):1651-1660. PubMed ID: 34139038
[TBL] [Abstract][Full Text] [Related]
12. Vibegron (Gemtesa) for overactive bladder.
Med Lett Drugs Ther; 2021 May; 63(1623):67-69. PubMed ID: 33976098
[No Abstract] [Full Text] [Related]
13. Low-dose Desmopressin and Tolterodine Combination Therapy for Treating Nocturia in Women with Overactive Bladder: A Double-blind, Randomized, Controlled Study.
Rovner ES; Raymond K; Andruczyk E; Juul KV
Low Urin Tract Symptoms; 2018 Sep; 10(3):221-230. PubMed ID: 28560762
[TBL] [Abstract][Full Text] [Related]
14. Systematic review and meta-analysis of the efficacy and safety of vibegron vs antimuscarinic monotherapy for overactive bladder.
Su S; Liang L; Lin J; Liu L; Chen Z; Gao Y
Medicine (Baltimore); 2021 Feb; 100(5):e23171. PubMed ID: 33592817
[TBL] [Abstract][Full Text] [Related]
15. Fesoterodine for the Treatment of Nocturnal Urgency in Patients with Overactive Bladder Syndrome: An Analysis of Responders and Nonresponders.
Khusid JA; Weiss JP; Carlsson MO; Mangan EK
J Urol; 2017 Nov; 198(5):1119-1123. PubMed ID: 28479240
[TBL] [Abstract][Full Text] [Related]
16. Additive effects of intravenous and intravesical application of vibegron, a β
Furuta A; Suzuki Y; Igarashi T; Koike Y; Kimura T; Egawa S; Yoshimura N
Naunyn Schmiedebergs Arch Pharmacol; 2020 Nov; 393(11):2073-2080. PubMed ID: 32556396
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of fesoterodine on nocturia and quality of sleep in Asian patients with overactive bladder.
Yokoyama O; Hiro S; Hotta S; Mogami S; Yamagami H
Urology; 2014 Apr; 83(4):750-5. PubMed ID: 24518285
[TBL] [Abstract][Full Text] [Related]
18. Vibegron: a β
Paton DM
Drugs Today (Barc); 2021 Aug; 57(8):507-517. PubMed ID: 34405208
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison.
Kennelly MJ; Rhodes T; Girman CJ; Thomas E; Shortino D; Mudd PN
Adv Ther; 2021 Nov; 38(11):5452-5464. PubMed ID: 34537953
[TBL] [Abstract][Full Text] [Related]
20. Re: Vibegron, a Novel Potent and Selective β3-Adrenoreceptor Agonist, for the Treatment of Patients with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study.
Wein AJ
J Urol; 2019 Aug; 202(2):218. PubMed ID: 31075074
[No Abstract] [Full Text] [Related]
[Next] [New Search]